# Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia

> **NCT05829460** · PHASE2 · WITHDRAWN · sponsor: **Washington University School of Medicine**

## Conditions studied

- Endometrial Hyperplasia

## Interventions

- **DRUG:** Semaglutide
- **DRUG:** Placebo
- **DRUG:** LNG-IUD (Progestin)
- **BEHAVIORAL:** Telemedicine behavioral weight program

## Key facts

- **NCT ID:** NCT05829460
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-03-12
- **Primary completion:** 2030-04-30
- **Final completion:** 2032-04-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2026-01-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05829460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05829460, "Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05829460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*